PALVELLA THERAPEUTICS, INC. 8-K

What Happened

• Palvella Therapeutics, Inc. filed a Form 8-K on February 24, 2026 reporting that it will host an investor conference call at 8:00 a.m. Eastern Time the same day to present topline results from its Phase 3 SELVA study of QTORIN™ 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations. The live event and slides are available at https://edge.media-server.com/mmc/p/9rjmec5z/. The company furnished the investor presentation as Exhibit 99.1 in the filing.

Key Details

• Event: Investor conference call and presentation on February 24, 2026 at 8:00 a.m. ET.
• Study: Phase 3 SELVA study of QTORIN™ 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations.
• Access: Live webcast and slides at https://edge.media-server.com/mmc/p/9rjmec5z/.
• Filing: Investor presentation furnished as Exhibit 99.1 to the Form 8-K (signed by CFO Matthew Korenberg).

Why It Matters

• Topline Phase 3 results are a material clinical milestone that can affect the company’s development timeline, regulatory path, and investor sentiment. Investors should review the presentation and listen to the call for the specific outcomes and any next steps the company outlines.